Neu-P11 Market

“Neu-P11 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about Neu-P11 for Alzheimer’s disease in Japan. A detailed picture of the Neu-P11 for Alzheimer’s disease in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Neu-P11 for Alzheimer’s disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Neu-P11 market forecast analysis for Alzheimer’s disease in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Alzheimer’s disease.

Drug Summary

Piromelatine, or Neu-P11, is a melatonin MT1, 2, and 3 and serotonin 5-HT-1A and -1D receptors agonist. Simultaneous activation of melatonergic and 5HT 1a receptors may synergistically promote neurogenesis. It is also reported to be a low-affinity antagonist of 5HT2B, P2X3, and TRPV1 receptors. Melatonin receptor agonism, which maintains the NREM SWS, appears beneficial for cognition and functioning in mild-to-moderate Alzheimer’s disease patients. Further, in preclinical studies in cell and animal models of Alzheimer’s disease, Piromelatine was found to protect from neural damage, facilitate memory performance improve cognitive impairment, and attenuate Alzheimer’s disease risk factors such as insulin resistance, hypertension, and sleep disorders.

Additionally, due to its multimodal mechanism, it is expected to improve memory and mood and increase cognition and neurogenesis, in addition to its proven effect of improving sleep, circadian rhythm control, enhancing slow-wave sleep, and reducing wakefulness during the night. 

The drug has completed a Phase II trial and is currently ongoing in a Phase II/III study in participants with mild dementia due to Alzheimer’s disease. The company is also investigating piromelatine for insomnia.

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the Neu-P11 description, mechanism of action, dosage and administration, research and development activities in Alzheimer’s disease.
• Elaborated details on Neu-P11 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Neu-P11 research and development activities in Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around Neu-P11.
• The report contains forecasted sales of Neu-P11 for Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for Neu-P11 in Alzheimer’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

Neu-P11 Analytical Perspective by DelveInsight

• In-depth Neu-P11 Market Assessment

This report provides a detailed market assessment of Neu-P11 for Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• Neu-P11 Clinical Assessment

The report provides the clinical trials information of Neu-P11 for Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Neu-P11 dominance.
• Other emerging products for Alzheimer’s disease are expected to give tough market competition to Neu-P11 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Neu-P11 in Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of Neu-P11 from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Neu-P11 in Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of Neu-P11?
• What is the clinical trial status of the study related to Neu-P11 in Alzheimer’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Neu-P11 development?
• What are the key designations that have been granted to Neu-P11 for Alzheimer’s disease?
• What is the forecasted market scenario of Neu-P11 for Alzheimer’s disease?
• What are the forecasted sales of Neu-P11 in Japan?  
• What are the other emerging products available and how are these giving competition to Neu-P11 for Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Alzheimer’s disease?